Stoke Therapeutics Presents Data For STK-002 Supporting Disease-Modifying Potential In Autosomal Dominant Optic Atrophy At AAO 2026 Annual Meeting
These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results - Stoke Therapeutics (NASDAQ
Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript